GSE210107
Differentiation of human cardiomyocyte and thymic epithelial cells from H1 control hESCs and H1 hESCs uniquely modified to be DNA methylated at the promoter CpG island of MLH1.
Engineering Pluripotent DNA Methylation by CpG Island Methylation Response (CIMR) to Synthetic CpG-free ssDNA Insertion Cellular differentiation requires global changes to DNA methylation (DNAme), where it functions  to regulate transcription factor and chromatin remodeling activity, and genome interpretation.  Here, we describe a simple DNAme engineering approach in pluripotent stem cells (PSCs),  extending across large stretches of CpG dense “islands (CGIs).” Integration of synthetic CpG free  single-stranded DNA (ssDNA) induces a target CpG Island Methylation Response (CIMR) in  multiple PSC lines, Nt2d1 embryonal carcinoma cells, and mouse PSCs, but not in highly  methylated CpG Island Methylator Phenotype (CIMP) positive cancer lines. CIMR DNAme at  MLH1 spans the CGI, is robustly maintained throughout cellular differentiation, suppresses target  gene activity, and sensitizes derived cardiomyocytes and thymic epithelial cells to the  chemotherapy cisplatin. Additional CIMR DNAme is reported on at TP53 and ONECUT1 CGIs.  Collectively, this new resource enables total CpG Island DNAme engineering in pluripotency and  the genesis of novel epigenetic models of development and disease Overall design: Modification of the MLH1 promoter to fully DNA methylated on one allele by CIMR induction. Differentiation of this MLH1-PM HESC line into human cardiomyocytes and thymic epithelial cells.